Capital Partners and the Bio Industry Organization invite you to
14th Annual Bio Investor Forum October 20-21, 2015 in San Francisco, CA.
Parc 55 San Francisco
55 Cyril Magnin Street
San Francisco, California, 94102
October 20-21, 2015
is the BIO Investor Forum?
The BIO Investor Forum is an international biotech investor
conference focused on early and established private companies as
well as emerging public companies. The event features plenary
sessions, business roundtables and therapeutic workshops, company
presentations, and One-on-One PartneringTM meetings.
Why Attend the BIO Investor Forum?
One of the only independent investor
conferences dedicated to helping early-stage biotech
companies find sources of capital.
Ideal venue for investors and
company executives to discuss financial and strategic
business issues affecting investment in biotech companies
and explore potential partnerships and business
collaborations to fuel research and development for
Attracts healthcare venture capital and
public market investors and research analysts as well as
business development executives from leading global
pharmaceutical and biotechnology companies.
Offers ample networking opportunities,
informative therapeutic and business workshops, and
presentations from up-and-coming companies.
Bio Investor Forum
Qualifying investors can attend the BIO Investor Forum free of
charge. The requirements for a qualifying investor are below.
CLICK HERE to register.
Qualified investors are defined as institutional, private equity,
angel and venture investors with funds on-hand, whose primary
activity is direct investment in research and development companies
(e.g., hedge fund, mutual fund, or venture fund). Equity research
analysts from investment banking institutions and buy-side analysts
also qualify as investors.
John Chambers, Vice-Chairman and Head of
Healthcare Investment Banking for ROTH Capital Partners, has been selected to the
Bio Investor Forum Advisory Committee
and will be Panelist for the "Status of the IPO
Appetite, M&A, Foreign Shocks, and Higher Interest Rates?"
Status of the IPO Appetite, M&A, Foreign Shocks,
and Higher Interest Rates?
Wednesday | October 21, 4:30 pm – 5:30 pm
While the appetite for new IPOs remains strong and cash is still
flowing freely in the capital intensive biotech
sector, concerns over valuation have the public markets on high
alert. Investment banks are competing
for the next biggest IPO with less clinical evidence in place up
front. As M&A among payers and among biopharmas start a new round of consolidation, what does all this
mean for privately held companies? Global
economic factors have had a serious impact across all sectors, but
how will biotech be affected? Has the
biotech sector’s resilience strengthened since the last downturn?
This panel of diverse experts will discuss
what we can learn from history and where the market is crossing a
Brian Hagerty, Senior Director, Capital Markets, New York Stock
John Chambers, Vice-Chairman and Head of Healthcare Investment
Banking, ROTH Capital Partners
Margarita Chavez, Director, Venture & Early Stage Collaborations, AbbVie Biotech Ventures
Asthika Goonewardene, Senior Biotech Analyst, Bloomberg
David Woodhouse, PhD, Chief Financial Officer, NGM
ROTH Capital Partners
888 San Clemente Dr. | Newport Beach, CA 92660 | (800) 678.9147 | roth.com | Member SIPC / FINRA